Search
- Dec 11, 2023
Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23
Arthur Sands elaborates on two programs Nurix presented updated data for at ASH and dives into the company's pipeline and partnerships.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A